• Chemotherapy comprised one of the following combinations for 3-6 cycles: cisplatin 50 mg/m 2 (d1) + cyclophosphamide 500 mg/m 2 (d1) + epirubicin 60 mg/m 2 (d1), or gemcitabine 900 mg/m 2 (d1, 8) + docetaxel 100 mg/m 2 (d8), or doxorubicin 60 mg/m 2 (d1) + ifosfamide 1.5 g/m 2 (d1-4). (heraldopenaccess.us)
  • Eralp Y, Saip P, Sakar B, Tas F, Aydiner A, Topuz E, "Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix," Eur J Gynaecol Oncol, 24(3-4):323-6 (2003). (yesimeralp.com)
  • Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: A French Federation of Cancer Institutes multicenter phase III randomized study. (trillium.de)
  • In patients with breast cancer receiving adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-D), we evaluated the impact of chemotherapy total cumulative dose (TCD), and early (FEC) versus late (D only) dose reductions, on survival outcomes. (jnccn.org)
  • The low incidence of adverse effects and chemotherapy dose changes, delays, and withdrawals supports the use of lenograstim as effective primary prophylaxis in South African patients being treated with a docetaxel-based regimen. (hindawi.com)
  • This study sought to retrospectively characterize outcomes for patients with node-negative and node-positive breast cancer receiving adjuvant trastuzumab in combination with docetaxel/cyclophosphamide (DCH), docetaxel/carboplatin/trastuzumab (TCH), or fluorouracil/epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (FEC-DH) chemotherapy in Alberta, Canada, from 2007 through 2014. (jnccn.org)
  • The initial dose of Herzuma is 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin ). (rxlist.com)
  • Her treatment included Mohs paste application, together with chemotherapy (four cycles of 5-fluorouracil, epirubicin, and cyclophosphamide, and four cycles of docetaxel). (biomedcentral.com)
  • Biocon Biologics Ltd), BT-ON013 - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
  • After high-dose CTCb (cyclophosphamide 6000 mg/m 2 , thiothepa 500 mg/m 2 , carboplatin 800 mg/m 2 , in 4 days), patients received PBSC infusion and daily C-CSF 300 μg subcutaneous injection. (johnshopkins.edu)
  • Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. (hemonc.org)
  • We suggest that the FE 120 C plus G-CSF is an effective and innovative regimen for PBSC mobilization in breast cancer patients, and high-dose CTCb therapy with PBSC support is a safe and well-tolerated treatment modality. (johnshopkins.edu)
  • METHODS: In the Italian multicentre Phase 3 randomised MIG-1 trial, node-positive and high-risk node- negative breast cancer patients were randomised to receive six cycles of adjuvant fluorouracil, epirubicin and cyclophosphamide regimen administered every 3 (FEC21) or 2 (FEC14) weeks. (unige.it)
  • Standard dosing regimen: As a single agent: 60-75 mg/m 2 once every 3-4 weeks or 1.2-2.4 mg/kg once every 3 weeks. (azurewebsites.net)
  • We applied four, five or six cycles of moderately high doses of doxorubicin and cyclophosphamide supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). (coek.info)
  • Average cumulative dose was also calculated for early (cycles 1-3) and late (cycles 4-6) chemotherapy. (jnccn.org)
  • Purpose: To determine the safety and efficacy of multiple cycles of dose-intensive, nonablative chemotherapy in women with poor-prognosis breast cancer. (tau.ac.il)
  • Patients and Methods: Women with stage II breast cancer and 10 or more involved nodes or four or more involved nodes and estrogen receptor- negative tumors and women with stage III disease received three cycles of epirubicin 200 mg/m 2 and cyclophosphamide 4 g/m 2 , with progenitor cell and filgrastim support every 28 days (n = 79) or 21 days (n = 20). (tau.ac.il)
  • Conclusion: Multiple cycles of dose-intensive, nonablative chemotherapy is a feasible and safe approach. (tau.ac.il)
  • the two groups then received an additional four cycles of pembrolizumab or placebo, and both groups received doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide. (themednet.org)
  • As conventional formulation: Dose reduction or longer intervals between cycles may be needed. (azurewebsites.net)
  • As conventional formulation: As a component of adjuvant therapy (multi-agent) in women with axillary lymph node involvement following resection of primary breast cancer: In combination with cyclophosphamide: 60 mg/m 2 on day 1 of each 21-day treatment cycle, for a total of 4 cycles. (azurewebsites.net)
  • Epirubicin Hydrochloride Injection should be administered only under the supervision of qualified physicians experienced in the use of cytotoxic therapy. (recallguide.org)
  • As with other cytotoxic agents, Epirubicin Hydrochloride Injection at the recommended dose in combination with cyclophosphamide and fluorouracil can produce severe leukopenia and neutropenia. (recallguide.org)
  • Total and differential WBC, red blood cell (RBC), and platelet counts should be assessed before and during each cycle of therapy with Epirubicin Hydrochloride Injection. (recallguide.org)
  • This toxicity appears to be dependent on the cumulative dose of Epirubicin Hydrochloride Injection and represents the cumulative dose-limiting toxicity of the drug. (recallguide.org)
  • If it occurs, delayed cardiotoxicity usually develops late in the course of therapy with Epirubicin Hydrochloride Injection or within 2 to 3 months after completion of treatment, but later events (several months to years after treatment termination) have been reported. (recallguide.org)
  • In a retrospective survey, including 9144 patients, mostly with solid tumors in advanced stages, the probability of developing CHF increased with increasing cumulative doses of Epirubicin Hydrochloride Injection (Figure 5). (recallguide.org)
  • In fact, reducing the planned dose intensity of systemic adjuvant chemotherapy regimens by as little as 15% has been shown to significantly reduce time to progression and overall survival rates in women with metastatic breast cancer [ 5 ]. (hindawi.com)
  • 85% for historical regimens (ie, cyclophosphamide/methotrexate/fluorouracil) are known to affect breast cancer survival. (jnccn.org)
  • Landmark meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in breast cancer mortality for first-generation regimens (ie, cyclophosphamide/methotrexate/fluorouracil [CMF]) and increased benefit with the addition of anthracyclines and taxanes. (jnccn.org)
  • Based on this evidence, guidelines published by the American Society of Clinical Oncology and the European Organisation for Research and Treatment of Cancer state that when the overall risk of FN is 20% or greater, especially on "dose dense" regimens, primary prophylaxis with G-CSFs is justified [ 10 , 13 ]. (hindawi.com)
  • Each multiple-dose vial of HERZUMA delivers 420 mg trastuzumab-pkrb, 839 mg α,α-trehalose dihydrate, 9.5 mg L-histidine HCl, 6.1 mg L-histidine, and 1.7 mg polysorbate 20. (rxlist.com)
  • Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. (hemonc.org)
  • This threshold, in addition to early versus late dose reductions, are poorly defined for third-generation anthracycline/taxane-based chemotherapy. (jnccn.org)
  • Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
  • WSG AM 01 randomized high-risk breast cancer patients to induction (2× epirubicin-cyclophosphamide) followed by tandem HD chemotherapy with epirubicin, cyclophosphamide and thiotepa versus dose dense chemotherapy (4× epirubicin-cyclophospamide followed by 3× cyclophosphamide-methotrexate-5-fluorouracil). (uu.nl)
  • Some drugs are more likely to cause nausea and vomiting when combined with certain other drugs or when given in high doses. (cancer.ca)
  • You may experience a serious allergic reaction while you receive a dose of doxorubicin lipid complex injection. (medlineplus.gov)
  • cyclophosphamide 600 mg/m 2 , i.v., day 1) plus G-CSF (300 μg/day, subcutaneous injection for 9 days, from day 4 post-FE 120 C) was used to mobilize PBSCs. (johnshopkins.edu)
  • A dose-dependent, reversible leukopenia and/or neutropenia is the predominant manifestation of hematologic toxicity associated with epirubicin and represents the most common acute dose-limiting toxicity of this drug. (recallguide.org)
  • Urotoxicity and myelosuppression is known as the most prevailing dose-limiting toxicity associated with CP. (researchwap.com)
  • Furthermore, they can lead to delays and dose reductions in chemotherapy treatment, thereby potentially compromising the efficacy of chemotherapy and, consequently, patient outcome [ 10 ]. (hindawi.com)
  • Efficacy of contraceptives may be reduced during administration of and for 28 days following the last dose of EMEND. (nih.gov)
  • Before beginning treatment with epirubicin, patients should recover from acute toxicities (such as stomatitis, neutropenia, thrombocytopenia, and generalized infections) of prior cytotoxic treatment. (recallguide.org)
  • Cyclophosphamide, [2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxzaphosphorine-2- oxide] is one of the most effective and widely used cytotoxic antitumor agents. (researchwap.com)
  • For which cytotoxic drugs is renal damage the dose-limiting toxicity? (freezingblue.com)
  • Dose-dense should be the preferred schedule of administration. (unige.it)
  • CONCLUSIONS: Updated results from the MIG-1 study are numerically in favour of dose-dense chemotherapy, and suggest a long- term benefit of this approach in high-risk early breast cancer patients. (unige.it)
  • Two (0.5%) patients and 32 (8.1%) patients had dose delayed due to febrile neutropenia and neutropenia, respectively. (hindawi.com)
  • Four (1.0%) patients and 32 (8.1%) patients had a dose changed due to febrile neutropenia and neutropenia, respectively. (hindawi.com)
  • Furthermore, lenograstim may increase the patient's exposure to chemotherapy allowing patients to receive optimal dosing and duration of treatment, benefitting survival. (hindawi.com)
  • High-dose therapy followed by peripheral blood stem cell (PBSC) support was performed in 29 patients with primary high-risk (Group I) or chemoresponsive metastatic (Group II) breast cancer patients. (johnshopkins.edu)
  • Group II patients had to achieve minimal residual disease (MRD) by induction chemotherapy before being considered eligible for PBSC mobilization and high-dose therapy. (johnshopkins.edu)
  • Cohort K enrolled 79 patients with MSI-H endometrial carcinoma and Cohort D enrolled 11 patients with MSI-H endometrial carcinoma for a total of 90 pooled patients who received KEYTRUDA as monotherapy (200 mg fixed dose every three weeks). (businesswire.com)
  • EMEND for oral suspension in pediatric patients 6 months to less than 12 years of age or pediatric and adult patients unable to swallow capsules: see dosing recommendations in Table 3 in the Full Prescribing Information. (nih.gov)
  • There is strong and consistent clinical evidence to show that granulocyte-colony stimulating factors (G-CSFs) reduce the risk of chemotherapy-induced neutropenia and therefore complicated neutropenia and can be used to maintain chemotherapy at the desired dose intensity or density and minimize delays in treatment [ 11 ]. (hindawi.com)
  • These effects do not usually predict subsequent development of delayed cardiotoxicity, are rarely of clinical importance, and are generally not considered an indication for the suspension of epirubicin treatment. (recallguide.org)
  • The radiation treatment included external pelvic irradiation (18 MV X-rays) with one fraction of 1.8-2.0 Gy daily for a total dose of 50 Gy in 5-6 weeks. (heraldopenaccess.us)
  • Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, "Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group," Cancer Investigation 21(5),737-43 (2003). (yesimeralp.com)
  • The recommended dose of epirubicin varies widely according to the specific condition being treated, the response to therapy, the other medications being used, and the body size of the recipient person receiving treatment. (medbroadcast.com)
  • Your chemo drugs will be given on a regular schedule in doses called rounds. (healthline.com)
  • Rats in group (8) received combination of V. amygdalina and O. gratissimum at a dose of 250 mg/kg each for ten consecutive before administering CP (200 mg/kg) on the tenth day. (researchwap.com)
  • If HERZUMA is reconstituted with SWFI without preservative, the reconstituted solution is considered single-dose. (rxlist.com)
  • Early cardiac toxicity of epirubicin consists mainly of sinus tachycardia and/or ECG abnormalities such as non-specific ST-T wave changes, but tachyarrhythmias, including premature ventricular contractions and ventricular tachycardia, bradycardia, as well as atrioventricular and bundle-branch block have also been reported. (recallguide.org)
  • One week after the last weekly dose of Herzuma, administer 6 mg/kg as an IV infusion over 30-90 minutes every three weeks to complete a total of 52 weeks of therapy. (rxlist.com)
  • As conventional formulation: Dose reduction may be needed. (azurewebsites.net)
  • Dose reduction, dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline). (azurewebsites.net)
  • Many things can affect the dose of a medication that a person needs, such as body weight, other medical conditions, and other medications. (medbroadcast.com)
  • Doses are usually given at 3- to 4-week intervals, either alone or with other medications used to treat cancer. (medbroadcast.com)
  • Cyclophosphamide (CP) is one of the most potent and widely used alkylating anticancer agents. (researchwap.com)
  • Many natural products have been widely reported to ameliorate at varying degrees the side effects of oxazophosphorines e.g. cyclophosphamide and ifosphamide (Łukasz and Piotr, 2012). (researchwap.com)
  • They may change the dose, give you another drug or have you take the drug in a different way. (cancer.ca)
  • In these cases, your doctor may want to change the dose, or other precautions may be necessary. (drugs.com)
  • If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. (drugs.com)
  • myelosuppression, gastrointestinal toxicity, and sterile hemorrhagic cystitis (cyclophosphamide and iphosphamide. (vin.com)
  • In limited-stage SCLC, the overall survival rate has been significantly improved by adding dose-hyperfractionated thoracic radiotherapy and prophylactic cranial irradiation to systemic chemotherapy. (ersjournals.com)
  • An increase in the total dose of chemotherapy seemed unlikely since other studies with dose-intensive chemotherapy failed to significantly improve survival [2,3]. (coek.info)
  • Rats in groups 4 and 5 received two different doses of O. gratissimum orally by gavage at 250 mg/kg and 500 mg/kg respectively for ten consecutive days before administering CP (200 mg/kg) on the tenth day. (researchwap.com)
  • The likelihood that radiation therapy will cause nausea and vomiting depends mostly on the area of the body being treated and the dose of radiation. (cancer.ca)
  • Higher doses of radiation are more likely to cause nausea or vomiting. (cancer.ca)
  • Initial dose may be infused up to 1 mg/minute, if tolerated, may increase rate to complete the infusion over 60 minutes. (azurewebsites.net)